Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PYC Therapeutics Limited ( (AU:PYC) ) just unveiled an announcement.
PYC Therapeutics has requested a trading halt in its securities on the ASX as it prepares a significant capital raising initiative. The halt will remain in place until either the completion announcement of the institutional component of a pro rata accelerated non-renounceable entitlement offer and an institutional placement, or the start of normal trading on 4 February 2026, whichever occurs first. The move signals an imminent equity raising that could strengthen the company’s balance sheet and fund its therapeutic development programs, with timing and structure designed to engage institutional investors while providing existing shareholders an opportunity to participate.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is an Australian biotechnology company listed on the ASX that focuses on developing therapeutic products, operating from its offices in Nedlands, Western Australia. The company targets healthcare and life sciences markets through research and development activities in therapeutics.
Average Trading Volume: 477,141
Technical Sentiment Signal: Buy
Current Market Cap: A$933.2M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.